Candel Therapeutics, Inc. (CADL) Tops Q2 EPS by 7c

Candel Therapeutics, Inc. (NASDAQ: CADL) reported Q2 EPS of ($0.09), $0.07 better than the analyst estimate of ($0.16).

For earnings history and earnings-related data on Candel Therapeutics, Inc. (CADL) click here.

You May Also Be Interested In

• Citi upgrades Bath & Body Works to Buy with $25 price target
• Duos Technologies Group, Inc. (DUOT) Tops Q2 EPS by 163c
• Fabrinet (FN) Tops Q4 EPS by 29c, Beats on Revenue; Offers Guidance